title: Bone marrow failure in children with acute liver failure.
abstract: BACKGROUND
  Aplastic anemia is a rare but well-recognized complication of acute hepatitis and acute liver failure. The cause is unknown, and the condition is fatal without bone marrow recovery. Treatment includes immunosuppression regimens or bone marrow transplantation. The purpose of this study was to investigate the incidence, cause, treatment, and outcomes of this disorder in children.
  
  
  METHODS
  Retrospective chart review of 75 patients with acute liver failure in a major pediatric liver center.
  
  
  RESULTS
  Eight patients had evidence of bone marrow failure. Of those, six had aplastic anemia, and two had transient bone marrow suppression. There were five boys, median age 57 months (range, 36-132 months). Two had parvovirus B19, six had non-A, non-B, non-C hepatitis. Five underwent liver transplantation: auxiliary in one, orthotopic in four. The interval between initial symptoms and development of aplastic anemia and/or bone marrow suppression was 21 to 99 days (median, 39 days). Four patients with aplastic anemia received intravenous antithymocyte globulin (ATG) or antilymphocyte globulin (ALG). Median recovery period of granulopoiesis was 62 days (range, 27-115 days). Two made a full recovery, one had myelodysplasia, and one with unresponsive disease died of septic complications. Four did not receive ATG/ALG, two had aplastic anemia, and two had bone marrow suppression. Three underwent liver transplantation, and all four resumed granulopoiesis. One child who underwent liver transplantation died of sepsis with chronic rejection. Median recovery of granulopoiesis was 99 days (range, 20-153 days).
  
  
  CONCLUSIONS
  Bone marrow failure occurs in 10.7% of children with acute liver failure. It sometimes occurs in association with non-A, non-B, non-C hepatitis and parvovirus B19 infection. Treatment with ATG/ALG is successful and is well tolerated in most cases.
authors.affiliation: Department of Child Health, King's College Hospital, United Kingdom.
authors.forename: J
authors.initials: J
authors.lastname: Tung
authors.forename: N
authors.initials: N
authors.lastname: Hadzic
authors.forename: M
authors.initials: M
authors.lastname: Layton
authors.forename: A J
authors.initials: AJ
authors.lastname: Baker
authors.forename: A
authors.initials: A
authors.lastname: Dhawan
authors.forename: M
authors.initials: M
authors.lastname: Rela
authors.forename: N D
authors.initials: ND
authors.lastname: Heaton
authors.forename: G
authors.initials: G
authors.lastname: Mieli-Vergani
mesh_terms: D000293:Adolescent; D000741:Anemia, Aplastic / Q000453:epidemiology / Q000209:etiology* / Q000628:therapy; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D001855:Bone Marrow Diseases / Q000453:epidemiology / Q000209:etiology* / Q000628:therapy; D002648:Child; D002675:Child, Preschool; D005260:Female; D006505:Hepatitis; D006801:Humans; D015994:Incidence; D007223:Infant; D007231:Infant, Newborn; D017114:Liver Failure, Acute / Q000150:complications*; D008297:Male; D016732:Parvovirus B19, Human; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000961:Antilymphocyte Serum